Related Experiment Video
Updated: May 21, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
1Department of Integrative Physiology and Bio-System Control, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan.
Abstract:
In recent years, peroxisome proliferator-activated receptor gamma (PPARγ) has been reported to be a target for the treatment of type II diabetes. Furthermore, it has received attention for its therapeutic potential in many other human diseases, including atherosclerosis, obesity, and cancers. Recent studies have provided evidence that the endogenously produced PPARγ antagonist, 2,3-cyclic phosphatidic acid (cPA), which is similar in structure to lysophosphatidic acid (LPA), inhibits cancer cell invasion and metastasis in vitro and in vivo. We recently observed that cPA negatively regulates PPARγ function by stabilizing the binding of the corepressor protein, silencing mediator of retinoic acid and thyroid hormone receptor. We also showed that cPA prevents neointima formation, adipocyte differentiation, lipid accumulation, and upregulation of PPARγ target gene transcription. We then analyzed the molecular mechanism of cPA's action on PPARγ. In this paper, we summarize the current knowledge on the mechanism of PPARγ-mediated transcriptional activity and transcriptional repression in response to novel lipid-derived ligands, such as cPA.
Insights
2,3-cyclic phosphatidic acid (cPA) inhibits cancer progression by negatively regulating peroxisome proliferator-activated receptor gamma (PPARγ). This novel lipid ligand stabilizes corepressor binding, repressing PPARγ transcriptional activity and preventing disease-related processes.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Peroxisome proliferator-activated receptor gamma (PPARγ) is a therapeutic target for type II diabetes and has potential in treating atherosclerosis, obesity, and cancers.
- 2,3-cyclic phosphatidic acid (cPA), an endogenous PPARγ antagonist, inhibits cancer cell invasion and metastasis.
- cPA shares structural similarities with lysophosphatidic acid (LPA).
Purpose of the Study:
- To elucidate the molecular mechanism by which cPA regulates PPARγ function.
- To summarize current knowledge on PPARγ-mediated transcriptional activity and repression by lipid-derived ligands like cPA.
Main Methods:
- Investigated the interaction between cPA, PPARγ, and corepressor proteins.
- Analyzed the effects of cPA on PPARγ target gene transcription.
- Examined cPA's impact on cellular processes regulated by PPARγ.
Main Results:
- cPA negatively regulates PPARγ activity by stabilizing the binding of the silencing mediator of retinoic acid and thyroid hormone receptor corepressor.
- cPA prevents neointima formation, adipocyte differentiation, and lipid accumulation.
- cPA inhibits the upregulation of PPARγ target gene transcription.
Conclusions:
- cPA acts as a novel PPARγ antagonist, offering therapeutic potential beyond cancer, including in metabolic and cardiovascular diseases.
- Understanding cPA's mechanism of action provides insights into regulating PPARγ transcriptional activity.
- cPA represents a promising therapeutic strategy for diseases involving PPARγ dysregulation.
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
GPCRs Regulate Adenylyl Cylase Activity
Two...
Master Transcription Regulators
Master Transcription Regulators
Co-activators and Co-repressors
Co-activators and Co-repressors
